pramlintide ๐Ÿถ Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
peptides and glycopeptides 2236 151126-32-8

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • symlin
  • pramlintide
  • pramlintide acetate
Pramlintide is an analog of human amylin. Amylin is colocated with insulin in secretory granules and cosecreted with insulin by pancreatic beta cells in response to food intake. Amylin and insulin show similar fasting and postprandial patterns in healthy individuals. In patients with type 1 and type 2 diabetes, there is reduced secretion from pancreatic beta cells of both insulin and amylin in response to food. Amylin affects the rate of postprandial glucose appearance through a variety of mechanisms, as determined by nonclinical studies. Amylin slows gastric emptying (i.e., the rate at which food is released from the stomach to the small intestine) without altering the overall absorption of nutrients. In addition, amylin suppresses glucagon secretion (not normalized by insulin alone), which leads to suppression of endogenous glucose output from the liver. Amylin also regulates food intake due to centrally-mediated modulation of appetite. In human studies, pramlintide, acting as an amylin analog, slows gastric emptying, reduces the postprandial rise in plasma glucagon, and modulates satiety leading to decreased caloric intake.
  • Molecular weight: 3949.44
  • Formula: C171H267N51O53S2
  • CLOGP:
  • LIPINSKI: None
  • HAC: 104
  • HDO: 56
  • TPSA: 1690.64
  • ALOGS:
  • ROTB: 109

Drug dosage:

None

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 1 Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 0.00 ยตM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
Vd (Volume of distribution) 0.41 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 15.30 mL/min/kg Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma) 0.40 % Lombardo F, Berellini G, Obach RS
t_half (Half-life) 0.60 hours Lombardo F, Berellini G, Obach RS

Approvals:

DateAgencyCompanyOrphan
March 16, 2005 FDA ASTRAZENECA AB

FDA Adverse Event Reporting System (Female)

None

FDA Adverse Event Reporting System (Male)

None

FDA Adverse Event Reporting System (Geriatric)

None

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC A10BX05 ALIMENTARY TRACT AND METABOLISM
DRUGS USED IN DIABETES
BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS
Other blood glucose lowering drugs, excl. insulins
FDA MoA N0000020064 Amylin Agonists
MeSH PA D007004 Hypoglycemic Agents
FDA EPC N0000177910 Amylin Analog

Drug Use (View source of the data)

DiseaseRelationSNOMED_IDDOID
Type 1 Diabetes Mellitus Treatment Adjunct indication
Type 2 Diabetes Mellitus Treatment Adjunct indication
Gastroparesis contraindication 235675006
Hypoglycemic disorder contraindication 237630007




๐Ÿถ Veterinary Drug Use

None

๐Ÿถ Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 9.88 acidic
pKa2 11.69 acidic
pKa3 11.79 acidic
pKa4 12.17 acidic
pKa5 12.18 acidic
pKa6 12.38 acidic
pKa7 12.45 acidic
pKa8 12.6 acidic
pKa9 12.65 acidic
pKa10 12.75 acidic
pKa11 12.85 acidic
pKa12 12.9 acidic
pKa13 12.95 acidic
pKa14 13.08 acidic
pKa15 13.09 acidic
pKa16 13.24 acidic
pKa17 13.33 acidic
pKa18 13.39 acidic
pKa19 13.43 acidic
pKa20 13.5 acidic
pKa21 13.65 acidic
pKa22 13.7 acidic
pKa23 13.72 acidic
pKa24 13.8 acidic
pKa25 13.93 acidic
pKa26 11.0 Basic
pKa27 10.4 Basic
pKa28 7.28 Basic
pKa29 6.56 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Amylin receptor AMY2 GPCR AGONIST EC50 8.64 SCIENTIFIC LITERATURE SCIENTIFIC LITERATURE
Amylin receptor AMY1 GPCR AGONIST EC50 9.45 SCIENTIFIC LITERATURE SCIENTIFIC LITERATURE
Amylin receptor AMY3 GPCR AGONIST EC50 9.05 SCIENTIFIC LITERATURE SCIENTIFIC LITERATURE

External reference:

IDSource
D05594 KEGG_DRUG
196078-30-5 SECONDARY_CAS_RN
4024910 VANDF
C0537551 UMLSCUI
CHEBI:135922 CHEBI
CHEMBL2103758 ChEMBL_ID
CHEMBL3833353 ChEMBL_ID
DB01278 DRUGBANK_ID
C105254 MESH_SUPPLEMENTAL_RECORD_UI
7482 IUPHAR_LIGAND_ID
7448 INN_ID
D3FM8FA78T UNII
16132446 PUBCHEM_CID
139953 RXNORM
19568 MMSL
66996 MMSL
d05488 MMSL
010717 NDDF
010718 NDDF
416392006 SNOMEDCT_US
416425000 SNOMEDCT_US
427360000 SNOMEDCT_US

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
SymlinPen HUMAN PRESCRIPTION DRUG LABEL 1 0310-6615 INJECTION 1000 ug SUBCUTANEOUS NDA 29 sections
SymlinPen HUMAN PRESCRIPTION DRUG LABEL 1 0310-6627 INJECTION 1000 ug SUBCUTANEOUS NDA 29 sections